Design | Patients | Indacaterol dose, μg | Pbo | For | Sal | Tio | |||||
---|---|---|---|---|---|---|---|---|---|---|---|
18.75 | 37.5 | 75 | 150 | 300 | 600 | ||||||
Cross-over, 14-day | 96 | 144‡ | 72 | 72 | |||||||
Parallel-group, 52-week | 1732 | 437 | 428 | 432 | 435 | ||||||
Parallel-group 26-week | 2059 | 130 | 420 | 418 | 123 | 425 | 123 | 420 | |||
Crossover, 14-day | 68 | 66 | 66 | 65 | |||||||
Parallel-group, 12-week | 416 | 211 | 205 | ||||||||
Parallel-group, 12-week | 347* | 114 | 116 | 117 | |||||||
Parallel-group, 26-week | 563 | 188 | 188 | 187 | |||||||
Parallel-group, 26-week | 1002 | 333 | 335 | 334 | |||||||
Parallel-group, 12-week | 323 | 163 | 160 | ||||||||
Parallel-group, 12-week | 318 | 159 | 159 | ||||||||
Parallel-group, 12-week | 552 | 92 | 91 | 94 | 92 | 91 | 92 | ||||
7476 | 92 | 91 | 546 | 1358 | 1369 | 551 | 2249 | 558 | 563 | 420 |